Cargando…

Severe hepatotoxicity due to osimertinib after nivolumab therapy in patients with non‐small cell lung cancer harboring EGFR mutation

BACKGROUND: Osimertinib is the most promising treatment option for patients with epidermal growth factor receptor (EGFR) mutation‐positive non‐small cell lung cancer (NSCLC) with acquired T790M resistance. However, recent studies have suggested that osimertinib could increase the frequency of seriou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yamaguchi, Ou, Kaira, Kyoichi, Kawasaki, Tomonori, Mouri, Atsuto, Hashimoto, Kosuke, Shiono, Ayako, Shinomiya, Shun, Miura, Yu, Nishihara, Fuyumi, Murayama, Yoshitake, Kobayashi, Kunihiko, Mochida, Satoshi, Kagamu, Hiroshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113047/ https://www.ncbi.nlm.nih.gov/pubmed/32068351 http://dx.doi.org/10.1111/1759-7714.13363

Ejemplares similares

Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non‐small cell lung cancer patients
por: Shiono, Ayako, et al.
Publicado: (2019)

Radiotherapy is an independent prognostic marker of favorable prognosis in non‐small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab
por: Yamaguchi, Ou, et al.
Publicado: (2019)

Different incidence of interstitial lung disease according to different kinds of EGFR‐tyrosine kinase inhibitors administered immediately before and/or after anti‐PD‐1 antibodies in lung cancer
por: Uchida, Takahiro, et al.
Publicado: (2019)

Clinicopathological impact of VEGFR2 and VEGF‐C in patients with EGFR ‐major mutant NSCLC receiving osimertinib
por: Kaira, Kyoichi, et al.
Publicado: (2023)

Clinical significance of primary prophylactic pegylated‐granulocyte‐colony stimulating factor after the administration of ramucirumab plus docetaxel in patients with previously treated non‐small cell lung cancer
por: Mouri, Atsuto, et al.
Publicado: (2019)

Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non‐small cell lung cancer: Management of adverse events
por: Miura, Yu, et al.
Publicado: (2020)

Combination of immune check inhibitor and immunomodulatory arabinomannan extracted from Mycobacterium tuberculosis: A case report
por: Kobayashi, Kunihiko, et al.
Publicado: (2021)

Tumor metabolic volume by (18)F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 ≥ 50%
por: Yamaguchi, Ou, et al.
Publicado: (2020)

Potential of FDG-PET as Prognostic Significance after anti-PD-1 Antibody against Patients with Previously Treated Non-Small Cell Lung Cancer
por: Hashimoto, Kosuke, et al.
Publicado: (2020)

Clinical impact of post‐progression survival on overall survival in patients receiving nivolumab monotherapy as a second‐line treatment for advanced non‐small cell lung cancer
por: Imai, Hisao, et al.
Publicado: (2021)

Pretreatment body mass index predicts survival among patients administered nivolumab monotherapy for pretreated non‐small cell lung cancer
por: Imai, Hisao, et al.
Publicado: (2022)

Effectiveness of EGFR‐TKI rechallenge immediately after PD‐1 blockade failure
por: Kaira, Kyoichi, et al.
Publicado: (2021)

Effect of Systemic Steroid Use for Immune-Related Adverse Events in Patients with Non-Small Cell Lung Cancer Receiving PD-1 Blockade Drugs
por: Mouri, Atsuto, et al.
Publicado: (2021)

Prognostic significance of tumor infiltrating lymphocytes on first-line pembrolizumab efficacy in advanced non-small cell lung cancer
por: Kaira, Kyoichi, et al.
Publicado: (2023)

Potential of VEGFR2 expression as a predictive marker of PD-1 blockade in patients with advanced NSCLC
por: Kaira, Kyoichi, et al.
Publicado: (2022)

Pre‐existing interstitial lung disease does not affect prognosis in non‐small cell lung cancer patients with PD‐L1 expression ≥50% on first‐line pembrolizumab
por: Yamaguchi, Ou, et al.
Publicado: (2020)

Efficacy and Feasibility of Programmed Death-1/Programmed Death Ligand-1 Blockade Therapy in Non-Small Cell Lung Cancer Patients With High Antinuclear Antibody Titers
por: Mouri, Atsuto, et al.
Publicado: (2021)

Single-Cell Analysis Reveals a CD4(+) T-cell Cluster That Correlates with PD-1 Blockade Efficacy
por: Kagamu, Hiroshi, et al.
Publicado: (2022)

Osimertinib induced cardiomyopathy: A case report
por: Shinomiya, Shun, et al.
Publicado: (2020)

Establishing a whole blood CD4(+) T cell immunity measurement to predict response to anti-PD-1
por: Yamaguchi, Ou, et al.
Publicado: (2022)

A phase II study of daily carboplatin plus irradiation followed by durvalumab for stage III non-small cell lung cancer patients with PS 2 up to 74 years old and patients with PS 0 or 1 from 75 years: NEJ039A (trial in progress)
por: Kaira, Kyoichi, et al.
Publicado: (2020)

Spontaneous aspiration of a long tree twig as foreign body
por: Hashimoto, Kosuke, et al.
Publicado: (2019)

Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib
por: Yamaguchi, Ou, et al.
Publicado: (2023)

Salvage Chemotherapy in Patients with Previously Treated Thymic Carcinoma
por: Kaira, Kyoichi, et al.
Publicado: (2021)

Clinical Effectiveness of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with a Poor Performance Status
por: Kaira, Kyoichi, et al.
Publicado: (2021)

Metachronous lesions in the orbit, retroperitoneum, and pleura of mucosa‐associated lymphoid tissue lymphoma: A case report
por: Shiono, Ayako, et al.
Publicado: (2022)

Primary thymic adenocarcinoma with an aggressive clinical course: An autopsy case showing signet ring cell‐like features
por: Shiono, Ayako, et al.
Publicado: (2020)

Intermittent administration of atezolizumab with combined carboplatin and etoposide therapy for patients with extensive‑disease small cell lung cancer
por: Tsuda, Takeshi, et al.
Publicado: (2023)

Tumor immunity is related to (18)F‐FDG uptake in thymic epithelial tumor
por: Imai, Hisao, et al.
Publicado: (2021)

Prospective assessment using (18)F-FDG PET/CT as a novel predictor for early response to PD-1 blockade in non-small-cell lung cancer
por: Yamaguchi, Ou, et al.
Publicado: (2022)

Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer
por: Imai, Hisao, et al.
Publicado: (2022)

Real‐world data of atezolizumab plus carboplatin and etoposide in elderly patients with extensive‐disease small‐cell lung cancer
por: Shiono, Ayako, et al.
Publicado: (2022)

Comparative analysis of different response criteria at early phase after PD-1 blockade in non-small lung cancer
por: Kaira, Kyoichi, et al.
Publicado: (2023)

Pretreatment glasgow prognostic score predicts survival among patients administered first-line atezolizumab plus carboplatin and etoposide for small cell lung cancer
por: Wasamoto, Satoshi, et al.
Publicado: (2023)

Pretreatment Glasgow prognostic score predicts survival among patients with high PD‐L1 expression administered first‐line pembrolizumab monotherapy for non‐small cell lung cancer
por: Imai, Hisao, et al.
Publicado: (2021)

Value of (18)F-FDG-PET to predict PD-L1 expression and outcomes of PD-1 inhibition therapy in human cancers
por: Kaira, Kyoichi, et al.
Publicado: (2021)

Perspective of Immune Checkpoint Inhibitors in Thymic Carcinoma
por: Kaira, Kyoichi, et al.
Publicado: (2021)

Advanced Research on Immune Checkpoint Inhibitor Therapy
por: Imai, Hisao, et al.
Publicado: (2022)

Lung Adenocarcinoma Harboring EGFR Kinase Domain Duplication (EGFR-KDD) Confers Sensitivity to Osimertinib and Nivolumab: A Case Report
por: Li, Jie, et al.
Publicado: (2020)

Hypothesis generative head-to-head study comparing efficacy of afatinib and osimertinib based on immunological biomarkers in Japanese NSCLC patients with EGFR mutations (Heat on Beat study)
por: Morikawa, Kei, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tffctt8m1vnu7di46oq9skbnce